Skip to main content
. 2013 Dec 5;289(6):3571–3590. doi: 10.1074/jbc.M113.513366

FIGURE 8.

FIGURE 8.

ADCC activity of anti-Her2 IgG1 antibodies containing Fc variants. The graph shows the percent of cells killed in an assay for antibody-dependent cellular cytotoxicity (% specific lysis) versus log10 of antibody concentration. A, percent of SK-BR-3 cells killed with anti-Her2 IgG1 containing the Fc variants of M01, M04, W23, W117, W125, and W141. B, percent of SK-BR-3 cells killed with anti-Her2 IgG1 containing the Fc variants of. M01, M04, W144, W165, W168, and W187. C, percent of JIMT-1 cells killed with anti-Her2 IgG1 containing the wild type Fc (wt), afucosylated wild type Fc (afuco-wt), variant W117 and afucosylated W117 (afuco-W117). D, percent of JIMT-1 cells killed with anti-Her2 IgG1 containing the wild type Fc (wt), afucosylated wild type Fc (afuco-wt), and variant W125 and afucosylated W125 (afuco-W125). The designation afuco preceding an alias means that the antibody lacks fucose on the glycan at Asn-297 of Fc region. The various human IgG1 antibodies used in these assays are indicated by aliases in the graph, and the substitutions contained in each antibody are indicated in Table 3. Effect concentrations at 50% of maximal killing (EC50, pm) are shown beside the designated Fc variants in the figure.